Table 2.
Anti-SARS-CoV-2 spike antibody responses of the study subjects before and 28 days after receiving the third-dose of the mRNA vaccine.
| Group 1 Full-dose mRNA-1273 (n = 100) | Group 2 Half-dose mRNA-1273 (n = 98) | Group 3 Full-dose BNT-162b2 (n = 100) | P values |
||||
|---|---|---|---|---|---|---|---|
| Group 1 vs. Group 2 | Group 1 vs. Group 3 | Group 2 vs. Group 3 | |||||
| Day 1 | Anti-S IgG (BAU/mL) Geometric means (95% CI) | 42.32 (35.97–49.79) | 54.80 (47.13–63.71) | 58.57 (50.10–68.48) | 0.0105 | 0.0023 | NS |
| Day 28 | Anti-S IgG (BAU/mL) Geometric means (95% CI) | 3039 (2675–3453) | 2253 (2007–2529) | 1764 (1542–2018) | 0.0004 | <0.0001 | 0.0128 |
| Folds change | 71.80 | 41.11 | 30.12 | <0.0001 | <0.0001 | 0.0043 | |
P values were calculated by Mann Whitney test.
95% CI = 95% confidence interval, NS = not significant.